Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9189736 | 0.93 | LMNA (0.41) | LMNASMN1; SMN2CYP2C19HIF1A | |
| SCHEMBL9171058 | 0.88 | LMNA (0.53) | LMNASMN1; SMN2CYP2C19HIF1A | |
| SCHEMBL7607980 | 0.87 | LMNA (0.47) | LMNASMN1; SMN2CYP2C19HIF1A | |
| SCHEMBL5162293 | 0.87 | LMNA (0.47) | LMNASMN1; SMN2CYP2C19HIF1A | |
| SCHEMBL5033195 | 0.85 | LMNA (0.45) | LMNASMN1; SMN2CYP2C19HIF1A | |
| SCHEMBL16801766 | 0.84 | LMNA (0.60) | LMNASMN1; SMN2CYP2C19HIF1A | |
| SCHEMBL10318442 | 0.84 | LMNA (0.44) | LMNASMN1; SMN2CYP2C19HIF1A | |
| SCHEMBL619808 | 0.83 | LMNA (0.60) | LMNASMN1; SMN2CYP2C19HIF1A | |
| SCHEMBL2763433 | 0.82 | LMNA (0.38) | LMNACYP2C19HIF1A | |
| SCHEMBL9009288 | 0.82 | LMNA (0.49) | LMNASMN1; SMN2CYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022106715-A1 | PROCEDURE FOR OBTAINING HIGH PURITY IOHEXOL | JUSTESA IMAGEN S.A.U. (ES) | 2022-05-27 | — | — | WO | claimed |
| CN-110590591-B | Preparation method of iodixanol and iohexol impurities | 浙江海洲制药有限公司 | 2022-05-17 | — | — | CN | claimed |
| US-20120184773-A1 | REDUCTION OF FUSED BICYCLIC IMPURITIES IN TRIIODINATED X-RAY CONTRAST MEDIA | MALLINCKRODT LLC (US) | 2012-07-19 | — | — | US | claimed |
| US-5948940-A | OXYALKYLATION OF5-ACETAMIDO-N,N-BIS(2,3-DIHYDROXYPROPYL)-2,4,6-TRIIODOPHTHAL IMIDE | NYCOMED IMAGING AS (NO) | 1999-09-07 | — | — | US | claimed |
| CN-116332787-B | Preparation method of contrast agent intermediate acetyl iodide | 安庆朗坤药业有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-116332787-A | Preparation method of contrast agent intermediate acetyl iodide | 安庆朗坤药业有限公司 | 2023-06-27 | — | — | CN | disclosed |
| WO-2022106715-A1 | PROCEDURE FOR OBTAINING HIGH PURITY IOHEXOL | JUSTESA IMAGEN S.A.U. (ES) | 2022-05-27 | — | — | WO | disclosed |
| CN-110590591-B | Preparation method of iodixanol and iohexol impurities | 浙江海洲制药有限公司 | 2022-05-17 | — | — | CN | disclosed |
| CN-110590591-B | Preparation method of iodixanol and iohexol impurities | 浙江海洲制药有限公司 | 2022-05-17 | — | — | CN | disclosed |
| EP-2935204-B1 | PURIFICATION OF X-RAY CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2018-09-05 | — | — | EP | disclosed |
| US-9938233-B2 | Purification of X-ray contrast agents | GE HEALTHCARE AS (NO) | 2018-04-10 | — | — | US | disclosed |
| US-20160304440-A1 | PURIFICATION OF X-RAY CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2016-10-20 | — | — | US | disclosed |
| US-20110021823-A1 | PROCESSING CRUDE IODIXANOL MIXTURE BY NANOFILTRATION | GE HEALTHCARE AS (NO) | 2011-01-27 | — | — | US | disclosed |
| US-20110021823-A1 | PROCESSING CRUDE IODIXANOL MIXTURE BY NANOFILTRATION | GE HEALTHCARE AS (NO) | 2011-01-27 | — | — | US | disclosed |
| US-20110021828-A1 | RECOVERING UNREACTED INTERMEDIATE FROM DESALINATED AND DESOLVENTIZED DIMERISATION REACTION MIXTURE BY ULTRAFILTRATION | GE HEALTHCARE AS (NO) | 2011-01-27 | — | — | US | disclosed |
| US-20110021828-A1 | RECOVERING UNREACTED INTERMEDIATE FROM DESALINATED AND DESOLVENTIZED DIMERISATION REACTION MIXTURE BY ULTRAFILTRATION | GE HEALTHCARE AS (NO) | 2011-01-27 | — | — | US | disclosed |
| US-7754920-B1 | Solvent reduction in crystallisation of intermediate for non-ionic X-ray contrast agents | GE HEALTHCARE AS (NO) | 2010-07-13 | — | — | US | disclosed |
| EP-0642492-B1 | 5,5'-/(1,3-PROPANEDIYL) BIS-/IMINO(2-OXO-2,1-ETHANEDIYL)ACETYLIMINO/BIS(2,4,6-TRIIODO-1,3-BENZENEDICARBOXYAMIDES), AND CONTRAST MEDIA CONTAINING THEM | BRACCO SPA (IT) | 1996-09-11 | — | — | EP | disclosed |
| EP-0642492-A1 | 5,5'-/(1,3-PROPANEDIYL) BIS-/IMINO(2-OXO-2,1-ETHANEDIYL)ACETYLIMINO/BIS(2,4,6-TRIIODO-1,3-BENZENEDICARBOXYAMIDES), AND CONTRAST MEDIA CONTAINING THEM. | DIBRA SPA (IT) | 1995-03-15 | — | — | EP | disclosed |
| US-5210300-A | PURIFICATION OF CRUDE IOVERSOL USING CONTINUOUS DEIONIZATION | MALINCKRODT MEDICAL, INC. (US) | 1993-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304440-A1 | PURIFICATION OF X-RAY CONTRAST AGENTS | TMEM97, OGFR, TMEM120A | LMNA 721/4885SMN1; SMN2 4009/4885CYP2C19 3870/4885 |
| US-20110021823-A1 | PROCESSING CRUDE IODIXANOL MIXTURE BY NANOFILTRATION | ADH1A, ADH1C, NISCH | LMNA 2242/4885SMN1; SMN2 4790/4885CYP2C19 3420/4885 |
| US-20110021828-A1 | RECOVERING UNREACTED INTERMEDIATE FROM DESALINATED AND DESOLVENTIZED DIMERISATION REACTION MIXTURE BY ULTRAFILTRATION | REN, RCC2, AVPR2 | LMNA 1966/4885SMN1; SMN2 4843/4885CYP2C19 3710/4885 |
| US-20120184773-A1 | REDUCTION OF FUSED BICYCLIC IMPURITIES IN TRIIODINATED X-RAY CONTRAST MEDIA | GBA2, XRCC5, PAICS | LMNA 866/4885SMN1; SMN2 4171/4885CYP2C19 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.